Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mario Lopez

Infectious Disease San Juan, PR Medical Doctor

NPI 1952355968 CMS profile 1130763

715 Ave Ponce De Leon, San Juan, PR 00917

Open in the dashboard

General payments

$8,576

26 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$55,996 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Mario Lopez of San Juan, PR is reported in the CMS Open Payments database as having received $8,576 across 26 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $55,996 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118 1
2023 General $125 1
2021 General $268 3
2020 General $128 6
2019 General $7,936 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mario Lopez
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Mario Lopez were reported at $118. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Mario Lopez Infectious Disease median Middle half National median
2019 $7,936 $190 $60–$862 $163
2020 $128 $124 $32–$606 $114
2021 $268 $148 $38–$905 $132
2022 $0 $166 $50–$834 $149
2023 $125 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $118 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $8,018 15 payments
  2. Janssen Pharmaceuticals, Inc $138 5 payments
  3. Teva Pharmaceuticals USA, Inc. $125 1 payment
  4. Gilead Sciences, Inc. $125 1 payment
  5. Abbott Laboratories $118 1 payment
  6. Mylan Specialty L.P. $23 1 payment
  7. Amarin Pharma Inc. $16 1 payment
  8. Allergan Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,360 2 payments
  2. Food and Beverage $1,188 23 payments
  3. Travel and Lodging $28 1 payment
Products named General payments · program years 2019–2025
  1. DOVATO $202 4 payments
  2. AUSTEDO $125 1 payment
  3. Veklury $125 1 payment
  4. CABENUVA $122 1 payment
  5. AVEIR $118 1 payment
  6. JULUCA $110 1 payment
  7. INVEGA SUSTENNA $58 1 payment
  8. INVEGA TRINZA $58 1 payment
  9. XARELTO $43 2 payments
  10. SYMTUZA $37 2 payments
  11. Other $74 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

200

Median for Internal Medicine: 777

Drug cost

$13,326

Median for Internal Medicine: $73,373

Branded share of claims

11.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 12 $11,658
Esomeprazole Magnesium Generic 13 $373
Losartan Potassium Generic 17 $197
Pantoprazole Sodium Generic 12 $188
Gabapentin Generic 23 $170
Metoprolol Succinate Generic 15 $135
Amlodipine Besylate Generic 14 $111
Montelukast Sodium Generic 13 $105
Rosuvastatin Calcium Generic 24 $95
Atorvastatin Calcium Generic 18 $84

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record